Beskrywing

A study by StrategyHelix indicates that the global companion animal vaccine market is expected to increase by US$ 1,247.9 miljoen van 2022 aan 2028, 'n CAGR van 5.6% gedurende die voorspellingsperiode.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2018-2021 en voorspel tot 2028 covering key market aspects like sales value for companion animal vaccine. The global companion animal vaccine market is segmented on the basis of technology, animal type, en streek. Based on technology, the global companion animal vaccine market is categorized into attenuated vaccines (LAV), inactivated vaccines, recombinant vaccines, toxoid vaccines, ander. The attenuated vaccines segment captured the largest share of the market in 2021. On the basis of animal type, the global companion animal vaccine market has been segmented into cats, honde, ander. The dogs segment held the largest share of the global companion animal vaccine market in 2021 and is anticipated to hold its share during the forecast period. In terms of geography, the global companion animal vaccine market has been segmented into Asia Pacific, Europa, Noord-Amerika, Rest of the World (RoW). In 2021, North America made up the largest share of revenue generated by the companion animal vaccine market.

The global companion animal vaccine market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Bioveta a.s., Boehringer Ingelheim International GmbH, Durvet Inc., Elanco Animal Health Incorporated, HIPRA S.A., Indian Immunologicals Ltd (IIL), Inner Mongolia Jinyu Group Co. Bpk., Merck & Co. Inc., Pulike Biological Engineering Inc., Tianjin Ringpu Bio-technology Co. Bpk., Virbac New Zealand Ltd., Zoetis Inc. Competitive landscape gives a description of the competitive nature of the global companion animal vaccine market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the companion animal vaccine market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Tegnologie: attenuated vaccines (LAV), inactivated vaccines, recombinant vaccines, toxoid vaccines, ander
Dier tipe: katte, honde, ander
Streek: Asiatiese Stille-Oseaan, Europa, Noord-Amerika, Rest of the World (RoW)
Jare oorweeg: hierdie verslag dek die tydperk 2018 aan 2028
Company mentioned: Bioveta a.s., Boehringer Ingelheim International GmbH, Durvet Inc., Elanco Animal Health Incorporated, HIPRA S.A., Indian Immunologicals Ltd (IIL), Inner Mongolia Jinyu Group Co. Bpk., Merck & Co. Inc., Pulike Biological Engineering Inc., Tianjin Ringpu Bio-technology Co. Bpk., Virbac New Zealand Ltd., Zoetis Inc.

Sleutelvoordele vir belanghebbendes

– Get a comprehensive picture of the global companion animal vaccine market
– Bepaal groeisektore en -neigings vir belegging

INHOUDSOPGAWE

Deel 1. Inleiding
– Omvang van die studie
– Studietydperk
– Geografiese omvang
– Navorsingsmetodologie
Deel 2. Companion animal vaccine market overview
Deel 3. Market breakdown by technology
– Attenuated vaccines (LAV)
– Inactivated vaccines
– Recombinant vaccines
– Toxoid vaccines
– Ander
Deel 4. Market breakdown by animal type
– Katte
– Honde
– Ander
Deel 5. Market breakdown by region
– Asiatiese Stille-Oseaan
– Europa
– Noord-Amerika
– Rest of the World (RoW)
Deel 6. Sleutel maatskappye
– Bioveta a.s.
– Boehringer Ingelheim International GmbH
– Durvet, Inc.
– Elanco Animal Health Incorporated
– HIPRA, S.A.
– Indian Immunologicals Ltd (IIL)
– Inner Mongolia Jinyu Group Co., Bpk.
– Merck & Co., Inc.
– Pulike Biological Engineering, Inc.
– Tianjin Ringpu Bio-technology Co., Bpk.
– Virbac New Zealand Ltd.
– Zoetis Inc.
Oor StrategyHelix
Vrywaring